Niagen Bioscience, Inc. (NAGE)
| Market Cap | 166.91M -71.1% |
| Revenue (ttm) | 122.29M -1.9% |
| Net Income | 10.24M -49.9% |
| EPS | 0.12 -48.7% |
| Shares Out | 79.29M |
| PE Ratio | 17.46 |
| Forward PE | 25.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,308,518 |
| Open | 2.320 |
| Previous Close | 2.520 |
| Day's Range | 2.050 - 2.340 |
| 52-Week Range | 2.050 - 7.950 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 11.92 (+466.27%) |
| Earnings Date | Nov 4, 2026 |
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-gra... [Read more]
Financial Performance
In 2025, Niagen Bioscience's revenue was $129.42 million, an increase of 29.95% compared to the previous year's $99.60 million. Earnings were $17.38 million, an increase of 103.30%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price target is $11.92, which is an increase of 466.27% from the latest price.
News
Niagen Bioscience reports Q4 EPS (1c), one estimate (3c)
Reports Q revenue $27.2M, consensus $31.9M. “During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating c...
Niagen Bioscience sees FY26 direct website revenue up 15%-20%
The company states: “For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year.
Niagen Bioscience Earnings Call Transcript: Q3 2026
Q3 sales were $27.2M, with a $1.2M net loss, positive adjusted EBITDA, and $2.6M operating cash flow. Q4 revenue is expected to improve sequentially as investments target 2027 growth across consumer, ingredients, clinics, skincare, and pharmaceuticals.
Niagen Bioscience Earnings release: Q3 2026
Niagen Bioscience released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Niagen Bioscience Quarterly report: Q3 2026
Niagen Bioscience has published its Q3 2026 quarterly earnings report on November 4, 2026.
Niagen Bioscience Slides: Q3 2026
Niagen Bioscience has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, t...
Niagen Bioscience Slides: Corporate presentation
Niagen Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Niagen Bioscience price target lowered to $10 from $11 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Niagen Bioscience (NAGE) to $10 from $11 and keeps a Buy rating on the shares after the company received notification that it…
Niagen Bioscience price target lowered to $9 from $10 at Canaccord
Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $9 from $10 and keeps a Buy rating on the shares.
Niagen Bioscience launches Niagen At-Home Injection Kit
Niagen Bioscience (NAGE) announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen At-Home Injection Kit, featuring the Company’s first ready-to-inject liquid formu...
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience Transcript: LD Micro 20th Annual Main Event Conference
Last year's revenue was ~$127M with $16M net income, supported by supplement, ingredient and IV sales. Priorities include rare-disease drug approvals, topical expansion and further buybacks.
Niagen Bioscience announces debut of Tru Niagen Skincare
Niagen Bioscience (NAGE) announced the debut of Tru Niagen Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen Skincare Innovation Lab. The product in…
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Beauty--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, t...
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Award--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, to...
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience launches ‘Don’t Get Old. Age Better.’ campaign
Niagen Bioscience (NAGE), announced the launch of “Don’t Get Old. Age Better.,” a new brand campaign for its Niagen brand and sub-brands Tru Niagen and Niagen Plus, featuring 11-time world…
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience enters start-up agreement with Mass General Brigham
Niagen Bioscience (NAGE) announced a Start-Up Agreement with Mass General Brigham to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen…
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience announces publication of preclinical study on CD38
Niagen Bioscience (NAGE) announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primar...
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Niagen Bioscience subsidiary engaged Red Sky Partners to support NB4168
Niagen Bioscience (NAGE) announces that its wholly owned subsidiary, NAD Pharmaceuticals, has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168. T...